Immunotherapy Trial Before Surgery for Kidney Cancer
Summary
ClinicalTrials.gov registered NCT07516366, a Phase 2 clinical trial evaluating pembrolizumab immunotherapy administered before nephrectomy surgery for patients with renal cell carcinoma. The single-arm study will assess pathological complete response rate, event-free survival, and safety endpoints at multiple U.S. trial sites.
What changed
A new clinical trial registration (NCT07516366) was added to the ClinicalTrials.gov database. The trial will evaluate pembrolizumab as neoadjuvant immunotherapy prior to surgical removal of the kidney (nephrectomy) in patients with renal cell carcinoma. Primary endpoints include pathological complete response rate and event-free survival at 3 years.
Healthcare providers and oncologists treating kidney cancer patients should note this trial represents an emerging treatment paradigm combining immunotherapy with surgery. Patients meeting enrollment criteria may benefit from consideration for trial participation. The study is registered as recruiting pending at U.S. sites.
What to do next
- Monitor ClinicalTrials.gov for enrollment status updates
- Review eligibility criteria for patient referral consideration
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.